GATC Health utilizes its Multiomics Advanced Technology (MAT) platform, which employs neural networks and machine learning to simulate human physiology, enhancing the accuracy and speed of drug discovery. The platform predicts the efficacy and safety of drug candidates with 90% accuracy before lab testing, significantly reducing the time and cost associated with traditional drug development processes.
Funding
$54.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery and development processes are lengthy, expensive, and have a high failure rate due to the difficulty in accurately predicting drug efficacy and safety in preclinical stages. This results in significant financial risks for pharmaceutical companies and delays in bringing new treatments to market.
Solution
GATC Health offers the Multiomics Advanced Technology (MAT) platform, an AI-driven solution that simulates human physiology to enhance the accuracy and speed of drug discovery. By leveraging neural networks and machine learning, MAT predicts the efficacy, safety, and potential off-target effects of drug candidates with a high degree of accuracy before lab testing. This enables pharmaceutical companies to identify promising drug candidates early in the development process, significantly reducing the time and cost associated with traditional methods. The platform's ability to emulate human biology through proprietary models allows for a more precise understanding of drug interactions and potential therapeutic outcomes. MAT can also be used to de-risk investments in drug candidates and pipelines by providing trial simulation capabilities.
Target Audience
The primary target audience includes pharmaceutical and biotech companies, financial institutions investing in biopharma, universities conducting genomics and drug discovery research, CROs and labs, health plans and providers, and government/non-profit organizations involved in public health initiatives.
Features
- Neural networks simulate human physiology to predict drug efficacy and safety.
- Machine learning algorithms analyze multiomics data to identify potential drug candidates.
- Prediction of drug efficacy and safety with a reported 90% accuracy before lab testing.
- Rapid drug discovery process, generating novel drug candidates in a significantly reduced timeframe.
- Proprietary models emulate human biology to tackle complex healthcare challenges.
- Capability to identify potential off-target effects of drug candidates.
- Integration with existing distribution channels for enhanced delivery and tracking of healthcare solutions.